Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma.

Cancer research·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.

Science translational medicine·2026
Same author

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.

Nature communications·2025
Same author

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.

Neuro-oncology·2024
Same author

Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation.

Nature metabolism·2024

Related Experiment Video

Updated: Jun 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

CAR-T cell manufacturing: Major process parameters and next-generation strategies.

Melanie Ayala Ceja1, Mobina Khericha1, Caitlin M Harris1

  • 1Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA.

The Journal of Experimental Medicine
|January 16, 2024
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy is a vital B-cell malignancy treatment. Effective manufacturing is key to improving CAR-T cell therapy safety, efficacy, and patient accessibility.

More Related Videos

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

3.3K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K

Related Experiment Videos

Last Updated: Jun 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

3.3K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncology

Background:

  • Chimeric antigen receptor (CAR)-T cell therapies represent a significant advancement in treating B-cell malignancies, offering strong curative potential.
  • The successful application of CAR-T cell therapies extends beyond hematologic cancers to solid tumors and autoimmune diseases.
  • Effective manufacturing processes are crucial for the safety, efficacy, and widespread accessibility of these advanced therapies.

Approach:

  • This review examines critical process parameters in autologous CAR-T cell manufacturing.
  • It also addresses regulatory considerations pertinent to CAR-T cell production.
  • Ongoing developments shaping next-generation CAR-T cell therapies are discussed.

Key Points:

  • Manufacturing parameters directly influence the safety, efficacy, and accessibility of CAR-T cell products.
  • Regulatory oversight is essential for ensuring the quality and consistency of CAR-T cell therapies.
  • Innovations in manufacturing are paving the way for future advancements in CAR-T cell therapy.

Conclusions:

  • Optimizing CAR-T cell manufacturing is paramount for realizing the full therapeutic potential of this approach.
  • Addressing manufacturing challenges will enhance treatment accessibility for a broader patient population.
  • Continued research and development in CAR-T cell manufacturing are vital for future therapeutic breakthroughs.